Status:
COMPLETED
Trial to Incentivise Adherence for Diabetes
Lead Sponsor:
Duke-NUS Graduate Medical School
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
21-70 years
Phase:
NA
Brief Summary
Type II diabetes is associated with a host of adverse and costly complications, including heart attacks, strokes, blindness, kidney failure, and severe neuropathy that may result in amputations. For t...
Detailed Description
Type II diabetes is associated with a host of adverse and costly complications, including heart attacks, strokes, blindness, kidney failure, and severe neuropathy that may result in amputations. For t...
Eligibility Criteria
Inclusion
- Participants need to be uncontrolled diabetics at Baseline. Uncontrolled diabetes is defined by a HbA1c level 8.0 or greater. Participants will be required to have at least 1 of 2 HbA1c readings 8.0 or greater in the past 6 months.
- Be prescribed at least one diabetic medication for at least three months and be willing to have this verified by a physician.
- Be Singaporean citizens or Permanent Residents.
- Be able to converse in English or Mandarin.
Exclusion
- Individuals on inject-able insulin therapy.
- Individuals with significant co-morbid conditions such that they are unlikely to be able to take their medications without assistance from a third party.
- Individuals who are pregnant.
- Individuals who fail the PARQ and do not obtain doctor's consent.
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2018
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT02224417
Start Date
March 1 2015
End Date
October 31 2018
Last Update
January 23 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
SingHealth Polyclinics (Geylang)
Singapore, Singapore, 389707
2
SingHealth Polyclinic (Bedok)
Singapore, Singapore, 469662